| Active, not recruiting | 2 | 385 | US | tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone | National Institute of Allergy and Infectious Diseases (NIAID), PPD | Heart Transplant | 04/25 | 04/25 | | |
| Not yet recruiting | N/A | 270 | NA | Synchronized Diaphragmatic Stimulation, Asymptomatic Diaphragmatic Stimulation, SDS, ADS, VisONE SDS | VisCardia Inc., Clinical Accelerator Ltd., Duke Clinical Research Institute | Heart Failure With Reduced Ejection Fraction | 07/27 | 12/27 | | |